Quantcast
Last updated on April 18, 2014 at 0:06 EDT

Latest PPAR modulator Stories

2012-10-09 22:19:00

Discovery of new biological pathway may help scientists redesign certain diabetes drugs to eliminate or reduce adverse side effects Many drugs work by "fixing" a particular biological pathway that's gone awry in a disease. But sometimes drugs affect other pathways too, producing undesirable side effects that can be severe enough to outweigh the drug's benefits. Such is the case for the thiazolidinedione drugs (also known as TZDs), which are used to treat type 2 diabetes. These are...

2009-05-28 07:00:00

LOS ALTOS, Calif., May 28 /PRNewswire/ -- InteKrin Therapeutics, Inc. announced today it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New OrleansSaturday, June 6, 2009 during the "Novel Diabetes Therapies in Development in Humans" session at 4:00 pm CDT. Dr. Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, will provide a summary of the latest clinical data supporting the design of...